<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03019991</url>
  </required_header>
  <id_info>
    <org_study_id>ASC08201501</org_study_id>
    <nct_id>NCT03019991</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China</brief_title>
  <official_title>A Study on Safety, Tolerability and Pharmacokinetics of Ritonavir-boosted Danoprevir in Single and Multiple Doses in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascletis Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascletis Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Pharmacokinetics of Danoprevir in single dose
      (100mg QD on day 1, day 4 and day 14) and Ritonavir-boosted Danoprevir (100mg QD on day 4 and
      day 14) in single and multiple doses (100mg BID on day 5 -day 13) in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>40 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum plasma concentration at steady-state (Css,max)</measure>
    <time_frame>Up to 16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Total area under the concentration-time curve form time 0 to 12 hours post-dose at steady-state</measure>
    <time_frame>Up to 16 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PK Group (Danoprevir,Ritonavir)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14;100mg BID on day 5 -day 13; Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13; Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13 for 14 days;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danoprevir</intervention_name>
    <description>Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13</description>
    <arm_group_label>PK Group (Danoprevir,Ritonavir)</arm_group_label>
    <other_name>ASC08</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13</description>
    <arm_group_label>PK Group (Danoprevir,Ritonavir)</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>RTV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  Healthy men or women based on history, physical examination, laboratory examination
             and ECG.

          -  Negative serum or urine pregnancy test result (sensitivity of 25 mIU or better) for
             women with childbearing potential within the 24-hour period before the first dose of
             study drugs

          -  Female patients with childbearing potential (menopause within 1 year) must agree to
             use two reliable forms of effective non-hormonal contraception (i.e., condoms,
             cervical barriers, intrauterine device, spermicides, or sponge), at least 1 of which
             must be a physical barrier method, during treatment and for at least 6 months
             following the last dose of ribavirin

          -  All male patients with female partners of childbearing potential must use two reliable
             forms of effective contraception (combined) during treatment and for 6 months
             following the last dose of ribavirin

          -  Others as specified in the detailed protocol

        Exclusion Criteria:

          -  Have medical history, or has disease, such as cardiovascular system, respiratory
             system, endocrine and metabolic system, urinary system, digestive system, blood
             system, nerve system disease or psychiatric disease and acute or chronic infectious
             diseases and malignant tumors.

          -  Has a history of drug or food allergy.

          -  Positive hepatitis A antibody，positive hepatitis B surface antigen， positive hepatitis
             C antibody，syphilis antibody or HIV antibody at screening.

          -  Had gastrointestinal surgery, vagotomy, intestinal resection or any possible
             interference with gastrointestinal peristalsis, pH or absorbed by surgery.

          -  Pregnant, lactating or menstrual period and unwilling to reliable contraception period
             women of childbearing age.

          -  Female partners have fertility and reliable contraceptive measures of men.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huoling Tang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ascletis Pharmaceuticals Co., Ltd.</affiliation>
  </overall_official>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2017</study_first_submitted>
  <study_first_submitted_qc>January 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2017</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics,Danoprevir</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lactams</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

